A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

Study Summary

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

Conditions

Non-cystic Fibrosis Bronchiectasis

Interventions / Drugs

Nebulized Ensifentrine Suspension; 3 mg Nebulized Placebo Solution

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment180 participants

Primary Completion—

Lead SponsorVerona Pharma plc

Data Retrieved2026-04-11 04:31:16.186869+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.